Trial Profile
An Open Label, Ascending Dose Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Capsaicin (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Centrexion Therapeutics
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 30 Oct 2017 According to a Centrexion Therapeutics media release, 6-month data from this trial will be presented at the American College of Rheumatology and the Association of Rheumatology Health Professionals' (ACR/ARHP) 2017 Annual Meeting.
- 20 Jul 2017 Results from this trial will be presented at the American Podiatric Medical Association's (APMA) 2017 Annual Scientific Meeting.